ArticleTargeted oncology2020
Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer.
Article in Targeted oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.Frontiers in immunology · 2020Pooled it
- Impaired natural killer cell migration in HIV-infected individuals is caused by TIGIT-mediated inhibition of HIF-1α-dependent glycolysis.Cell death & disease · 2025Article
- Natural Killer Cell Activity and Response to Neoadjuvant Treatment in Breast Cancer Patients.International journal of molecular sciences · 2025Article
- Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Cellular plasticity and non-small cell lung cancer: role of T and NK cell immune evasion and acquisition of resistance to immunotherapies.Cancer metastasis reviews · 2025Review
- Predictive value of peripheral blood CD4Frontiers in immunology · 2025Article
- Autofluorescence lifetime imaging classifies human B and NK cell activation state.Frontiers in bioengineering and biotechnology · 2025Article
- Targeting innate and adaptive immunity to suppress lung cancer metastasis.Frontiers in immunology · 2025Review
- Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC.Cancer biomarkers : section A of Disease markers · 2025Article
- Natural Killer Cells in Cancers of Respiratory System and Their Applications in Therapeutic Approaches.Immunity, inflammation and disease · 2024Review
- A Novel Prognostic Nomogram Based on TIGIT and NKG2A Can Predict Relapse-Free Survival of Hepatocellular Carcinoma After Hepatectomy.Cancer medicine · 2024Article
- Interferon-Gamma Secretion Is Significantly Decreased in Stage III Breast Cancer Patients.International journal of molecular sciences · 2024Article
- Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.Frontiers in immunology · 2024Article
- Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers.Cancer chemotherapy and pharmacology · 2023Review
- Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer.Journal for immunotherapy of cancer · 2023Review
- Article
- NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.British journal of cancer · 2023Article
- The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer.Thoracic cancer · 2023Article
- A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.Frontiers in immunology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundImmunotherapy with immune checkpoint inhibitors for non-small cell lung cancer (NSCLC) has emerged as an important treatment option. Although immunotherapy may significantly improve survival and quality of life, response rates are as low as 20% in NSCLC patients.
objectiveThe identification of reliable biomarkers predicting response to immunotherapy is required urgently to determine patient selection guidelines. PATIENTS AND
methodsPeripheral blood mononuclear cells (PBMCs) from nine NSCLC patients were collected pre- and post-treatment with immunotherapy. The immune cell composition of PBMCs was analyzed using CyTOF with an optimized 32-marker panel. The natural killer (NK) cell activity was assessed with the measurement of interferon (INF)-γ using an NK Vue™ kit.
resultsWe found that the percentages of NK cell populations in the immune cells of PBMCs were prominently elevated in the immunotherapy responder group when compared with non-responders. While no meaningful differences were observed in other populations of immune cells, consistent with these results, the overall activity of NK cells in responders was highly elevated compared with that of non-responders. From the analysis of NK subsets, although differences in the population of early NK cells were not observed, the functionally differentiated late NK cells were prominently high in responders.
conclusionsThe overall activity or number of NK cells may be a useful biomarker to predict immunotherapy response in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.